



# LANTHEUS™

April 7, 2023

Dear Nuclear Medicine Professional,

We are pleased to announce that effective Sunday, April 9, 2023, all TechneLite® (Technetium Tc 99m Generator) units will be 100% low-enriched uranium (LEU) generators. For more than 55 years, Lantheus has been a leader and innovator in the Tc 99m generator market. We first received FDA approval for the commercial use of LEU in 2010. In January 2013, TechneLite® became the first technetium Tc 99m generator in the United States that contains at least 95% non-highly enriched uranium (HEU)-sourced molybdenum-99 (Mo-99) meeting the Centers for Medicare and Medicaid Services (CMS) criteria for the incremental add-on Hospital Outpatient Prospective Payment System (HOPPS) payment.

As a leader in the radiopharmaceutical business, Lantheus has developed a world class, globally diversified and balanced Mo-99 supply chain. We receive Mo-99 from three of the four major processors and five of the six associated reactors in the world. Through this supply chain, we have been the most reliable supplier of Tc 99m generators, providing TechneLite® to nuclear medicine customers with over 95% of units being LEU over the past twelve months. Through the efforts of the Lantheus team and our supply chain partners, our conversion to 100% LEU-derived Mo-99 is complete, ensuring that our customers will now have full access to LEU TechneLite® generators.

As always, we appreciate your support and thank you for your business.

Sincerely,

John Wiggins  
Vice President, Isotope Strategy and SPECT Franchise